SmartZyme, a Ness Ziona, Israel and NYC-based biopharmaceutical company, closed $4m funding round.
The round was led by healthcare investment firm OrbiMed. In conjunction with the funding, Nissim Darvish, M.D., Ph.D., senior managing director at OrbiMed Israel, and Stephen Squinto, Ph.D., venture partner at OrbiMed, joined SmartZyme’s board of directors.
The company intends to use the funds to continue developing new therapeutics using their Provolution protein technology and to improve the administration of existing biologics as they prepare to license the innovative enzyme and device for diabetic blood glucose monitoring.
Founded in November 2013 by Shilo Ben Zeev and David Baram, Ph.D., SmartZyme uses proprietary Provolution™ platform for protein design and engineering of both new and better therapeutics.